Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · page 5 of 37
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.
Pitch deck · problem_statement · frame_problem · dense density
Slide locked Sign in to view
Slide schematic 4/4
chart 1/1 paragraph 1/1 source-note 1/1 title 1/1
Components 4
scatter paragraph source-note headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1